• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Bydureon, Bydureon BCise (exenatide extended-release for injectable suspension)

AND
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Bydureon, Bydureon BCise (exenatide extended-release for injectable suspension)

  • Profile

Profile

Contact Information

Contact: AstraZeneca
Website: https://www.bydureon.com/bydureon-bcise/

Currently Enrolling Trials

    Show More

    General Information

    Bydureon is an extended-release formulation of exenatide, a GLP-1 receptor agonist that enhances glucose-dependent insulin secretion by the pancreatic beta-cell, suppresses inappropriately elevated glucagon secretion, and slows gastric emptying.

    Bydureon is specifically indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type II diabetes mellitus.

    Bydureon is supplied as a powder suspension to be reconstituted into a solution. The recommended dose is 2 mg administered once every seven days (weekly). The dose can be administered at any time of day, with or without meals. Bydureon is administered as a subcutaneous (SC) injection in the abdomen, thigh or upper arm region.

    Mechanism of Action

    Bydureon is an extended-release formulation of exenatide, a GLP-1 receptor agonist that enhances glucose-dependent insulin secretion by the pancreatic beta-cell, suppresses inappropriately elevated glucagon secretion, and slows gastric emptying. The amino acid sequence of exenatide partially overlaps that of human GLP-1. Exenatide is a GLP-1 receptor agonist that has been shown to bind and activate the human GLP-1 receptor in vitro. This leads to an increase in both glucose-dependent synthesis of insulin and in vivo secretion of insulin from pancreatic beta cells, by mechanisms involving cyclic AMP and/or other intracellular signaling pathways. Exenatide promotes insulin release from pancreatic beta cells in the presence of elevated glucose concentrations.

    Side Effects

    Adverse effects associated with the use of Bydureon may include, but are not limited to, the following:

    • nausea
    • diarrhea
    • headache
    • vomiting
    • constipation
    • injection site pruritus
    • injection site nodule
    • dyspepsia

    Clinical Trial Results

    The FDA approval of Bydureon was based on a 24-week comparator-controlled study. This randomized, open-label trial was conducted to compare the safety and efficacy of Bydureon to Byetta in 252 subjects with type II diabetes and inadequate glycemic control with diet and exercise alone or with oral antidiabetic therapy, including metformin, a sulfonylurea, a thiazolidinedione, or combination of two of those therapies. The subjects were randomly assigned to receive Bydureon 2 mg once every seven days (weekly) or Byetta (10 mcg twice-daily), in addition to existing oral antidiabetic agents. Subjects assigned to Byetta initiated treatment with 5 mcg twice-daily then increased the dose to 10 mcg twice-daily after 4 weeks. The mean baseline HbA1c was 8.4%. The primary endpoint was change in HbA1c from baseline to Week 24 (or the last value at time of early discontinuation). The mean change from baseline was for Bydureon -1.6 and for -0.9 Byetta. The percentage achieving HbA1c <7% at Week 24 was 58% in the Bydureon arm and 30% in the Byetta arm. Reductions from mean baseline (97/94 kg) in body weight were observed in both Bydureon (-2.3 kg) and Byetta (-1.4 kg) treatment groups.

    Approval Date: 2012-01-01
    Company Name: AstraZeneca
    Back to Listings

    Upcoming Events

    • 25May

      2022 WCG Avoca Quality & Innovation Summit: Own the Future

    • 28Jun

      Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

    • 16Oct

      WCG MAGI's Clinical Research Hybrid Conference - 2022 West

    Featured Products

    • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

      Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    Featured Stories

    • Protocol-360x240.png

      Avoid Deviations by Making Protocol Review a Team Effort

    • SelectionProcess-360x240.png

      Give Us a Voice: Sites Clamor for a Say on Vendor Selection

    • Convince-360x240.png

      Use Data and Details to Convince Site Leadership to Add Staff

    • AsktheExpertsBadge-360x240.png

      Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell My Personal Information

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 617.948.5100 – Toll free 866.219.3440

    Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing